169310-73-0

Usage

Uses

Used in Pharmaceutical Industry:
Benzene, 1-methoxy-4-[(3-methyl-3-butenyl)oxy]is used as an intermediate in the synthesis of L-Isomer of Mevalonic acid (M339020) for its role as a precursor in the biosynthesis of cholesterol (C432501). This makes it a valuable component in the development of drugs targeting cholesterol metabolism and related conditions.

Upstream product

• 763-32-6 2-methyl-1-buten-4-ol 
• 150-76-5 4-methoxy-phenol 
• 80352-66-5 4-mesyloxy-2-methylbutene 

Downstream Products

• 169310-89-8 (2R)-4-(4-methoxyphenoxy)-2-methylbutane-1,2-diol 
• 209118-78-5 (2S)-4-(4-methoxyphenoxy)-2-methylbutane-1,2-diol 
• 915769-85-6 (2S)-1-furan-3-yl-4-(4-methoxyphenoxy)-2-methylbutan-2-ol 
• 915769-86-7 3-[(2S)-2-benzyloxy-4-(4-methoxyphenoxy)-2-methylbutyl]furan 
• 915769-87-8 3-[(2S)-2-benzyloxy-4-(4-methoxyphenoxy)-2-methylbutyl]-2-bromofuran 
• 915769-88-9 (2S)-{3-[2-benzyloxy-4-(4-methoxyphenoxy)-2-methylbutyl]furan-2-yl}dimethylvinylsilane 
• 915769-83-4 (2S)-2-({3-[2-benzyloxy-4-(4-methoxyphenoxy)-2-methylbutyl]furan-2-yl}dimethylsilanyl)ethanol 
• 915769-91-4 4-[2-({3-[(2S)-2-benzyloxy-4-(4-methoxyphenoxy)-2-methylbutyl]furan-2-yl}dimethylsilanyl)ethoxy]-2,3,5,6-tetrabromophenol 
• 915769-90-3 3-[(2S)-2-benzyloxy-4-(4-methoxyphenoxy)-2-methylbutyl]-2-(dimethyl-{2-[2,3,5,6-tetrabromo-4-(tert-butyldimethylsilanyloxy)phenoxy]ethyl}silanyl)furan 
• 915769-81-2 (2R,3R,4R,6R)-3,4-bis(benzyloxy)6-{2-[(2-{4-[2-({3-[(2S)-2-benzyloxy-4-(4-methoxyphenoxy)-2-methylbutyl]furan-2-yl}dimethylsilanyl)ethoxy]-2,3,5,6-tetrabromophenoxy}ethyl)dimethylsilanyl]furan-3-yl}-2-methyltetrahydropyran 
• 950698-10-9 C₁₈H₂₄O₅ 
• 237393-21-4 (R)-2-hydroxy-4-(4-methoxyphenoxy)-2-methylbutyl 2,2,2-trimethylacetate 
• 944943-11-7 (3R,4R,6S)-7-(4-methoxyphenoxy)-3,6-dimethyl-3,4-bis[(triethylsilyl)oxy]heptan-1-ol 
• 944943-13-9 (3R,4R,6S)-7-(4-methoxyphenoxy)-3,6-dimethyl-3,4-bis[(triethylsilyl)oxy]heptaldehyde 

Relevant academic research and scientific papers

PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF

Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g, protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g, a cancer or a metabolic disease.

Chiral heterocyclic tert-alcohol intermediate preparation method and application thereof

The invention provides a preparation method of a chiral eterocyclic tert-alcohol intermediate and a method for preparing 1,4-dihydropyridine-3,5-dicarboxylic ester derivative by the chiral eterocyclictert-alcohol intermediate. Through the method, the reac

7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral Leishmaniasis

Within a backup program for the clinical investigational agent pretomanid (PA-824), scaffold hopping from delamanid inspired the discovery of a novel class of potent antitubercular agents that unexpectedly possessed notable utility against the kinetoplast

A ring-closing enyne metathesis approach to functionalized semicyclic dienes: The total synthesis of (-)-tetrangomycin

The angucycline antibiotic (-)-tetrangomycin was synthesized in 13 steps (11 % overall yield) by using a stereoselective Diels-Alder reaction between a naphthoquinone and a semicyclic diene to construct the benz[a]anthraquinone ring system. The diene inte

A Ring-Closing Enyne Metathesis Approach to Functionalized Semicyclic Dienes: The Total Synthesis of (-)-Tetrangomycin

The angucycline antibiotic (-)-tetrangomycin was synthesized in 13 steps (11 % overall yield) by using a stereoselective Diels-Alder reaction between a naphthoquinone and a semicyclic diene to construct the benz[a]anthraquinone ring system. The diene inte

Synthesis of phosphoantigens: Scalable accesses to enantiomers of BrHPP and studies on N-HDMAPP synthesis

Phosphoantigens enable the access to a new anti-tumoral and anti-infectious therapeutic pathway, based on innate immunity through the selective activation of Tγ9δ2 lymphocytes. The first proof of concept of this new immunotherapy approach was demonstrated

Total synthesis of nominal lyngbouilloside aglycon

The first enantioselective total synthesis of the originally assigned structure of lyngbouilloside aglycon has been achieved using a particularly flexible route featuring an acylketene macrolactonization of a tertiary methyl carbinol as the key step. Comp

Total synthesis of amphidinolide y by formation of trisubstituted (E)-double bond via ring-closing metathesis of densely functionalized alkenes

Amphidinolide Y, a 17-membered cytotoxic macrolide isolated from marine dinoflagellates, has been synthesized via ring-closing metathesis to assemble the congested trisubstituted (E)-double bond. The seco precursor was prepared from readily available chir

A new synthesis of tetrahydrofuran fragment of amphidinolides X and Y

A new synthesis of the tetrasubstituted tetrahydrofuran fragment of the marine secondary metabolites amphidinolides X and Y is described. The oxygenated chiral quaternary carbon was assembled by asymmetric dihydroxylation in high enantioselectivity and th

C-aryl glycosides via tandem intramolecular benzyne-furan cycloadditions. Total synthesis of vineomycinone B2 methyl ester

A triply convergent total synthesis of vineomycinone B2 methyl ester has been achieved by an approach with a longest linear sequence of 16 steps. The synthesis features the use of silicon tethers as disposable linkers to control the regiochemis